Fibroblast-based radiosensitivity assays as a clinically valuable tool for (severe) combined immunodeficiency syndromes.

Genetic defects in one of the DNA double strand break (DSB) repair proteins lead to distinct human syndromes with severe clinical manifestations, including impaired neurological and immunological development, cancer proneness and sensitivity to ionizing radiation. Since diagnostic and therapeutic procedures frequently use DNA damaging agents, identification of radiosensitive individuals is imperative to optimize patient management. However, patients with a (severe) combined immunodeficiency (S)CID are often ineligible for lymphocyte-based radiosensitivity testing. Therefore, this study investigated the suitability of two fibroblast-based assays as alternative methods. DSB repair was evaluated following X-ray irradiation by an optimized cytokinesis-block micronucleus (MN) assay and the γH2AX focus test in fibroblasts from patients with a confirmed or suspected diagnosis of radiosensitive (S)CID. Using both assays, patients with a defect in Artemis were identified as radiosensitive while those with a RAG1/2 deficiency were not considered as radiosensitive. Although MN scoring was not feasible in irradiated fibroblasts deficient in XLF, LIG4 or NBS1, radiosensitivity could be readily demonstrated through impaired DNA DSB repair kinetics with the γH2AX focus assay in fibroblasts deficient in XLF or LIG4, but not in those deficient in NBS1. While both ATM defective fibroblasts clearly showed increased radiation-induced MN yields, one of the two fibroblast cell lines could not be identified as radiosensitive based on residual γH2AX focus levels. This study suggests that combining the fibroblast MN assay and γH2AX focus test can effectively exclude in vitro radiosensitivity in patients with a suspicion of radiosensitive (S)CID, particularly when lymphocyte-based radiosensitivity testing is not feasible.